{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T04:01:22Z","timestamp":1793073682962,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008087","name":"Guthy-Jackson Charitable Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008087","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K08 NS078555"],"award-info":[{"award-number":["K08 NS078555"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015250","name":"NIHR Bristol Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015250","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["DFG Exc 257"],"award-info":[{"award-number":["DFG Exc 257"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000890","name":"National Multiple Sclerosis Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000890","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.msard.2018.12.011","type":"journal-article","created":{"date-parts":[[2018,12,9]],"date-time":"2018-12-09T09:12:36Z","timestamp":1544346756000},"page":"64-68","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":75,"special_numbering":"C","title":["Long-term disability in neuromyelitis optica spectrum disorder with a history of myelitis is associated with age at onset, delay in diagnosis\/preventive treatment, MRI lesion length and presence of symptomatic brain lesions"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8967-6338","authenticated-orcid":false,"given":"Maureen A.","family":"Mealy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Mossburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadja","family":"Borisow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reydmar","family":"Lopez-Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0556-6364","authenticated-orcid":false,"given":"Juan Pablo","family":"Ospina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Scheel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anusha K.","family":"Yeshokumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amine","family":"Awad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Isabel","family":"Leite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JorgeA. Jimenez","family":"Arango","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedemann","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Palace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7969-8346","authenticated-orcid":false,"given":"Michael","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"February (2)","key":"10.1016\/j.msard.2018.12.011_bib0001","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/1352458515581438","article-title":"Treatment of acute relapses in neuromyelitis optica: steroids alone versus steroids plus plasma exchange","volume":"22","author":"Abboud","year":"2016","journal-title":"Mult. Scler."},{"issue":"July (1)","key":"10.1016\/j.msard.2018.12.011_bib0002","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1212\/WNL.0b013e318297ef07","article-title":"Evolution of longitudinally extensive transverse myelitis in an aquaporin-4 IgG-positive patient","volume":"81","author":"Asgari","year":"2013","journal-title":"Neurology"},{"issue":"Jun(6)","key":"10.1016\/j.msard.2018.12.011_bib0003","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/j.1468-1331.2010.03252.x","article-title":"Evaluation of health-related quality of life, fatigue and depression in neuromyelitis optica","volume":"18","author":"Chanson","year":"2011","journal-title":"Eur. J. Neurol."},{"issue":"October (6)","key":"10.1016\/j.msard.2018.12.011_bib0004","doi-asserted-by":"crossref","first-page":"e286","DOI":"10.1212\/NXI.0000000000000286","article-title":"Insufficient treatment of severe depression in neuromyelitis optica spectrum disorder","volume":"3","author":"Chavarro","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"Jul(8)","key":"10.1016\/j.msard.2018.12.011_bib0005","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1177\/1352458513515085","article-title":"Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset","volume":"20","author":"Collongues","year":"2014","journal-title":"Mult. Scler."},{"issue":"October(3)","key":"10.1016\/j.msard.2018.12.011_bib0006","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1212\/NXI.0000000000000034","article-title":"Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO.","volume":"1","author":"Gelfand","year":"2014","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"May(19)","key":"10.1016\/j.msard.2018.12.011_bib0007","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1212\/WNL.0000000000002655","article-title":"Evaluation of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorder","volume":"86","author":"Hyun","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2018.12.011_bib0008","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1742-2094-9-14","article-title":"Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients","volume":"9","author":"Jarius","year":"2012","journal-title":"J. Neuroinflammation"},{"issue":"July(5)","key":"10.1016\/j.msard.2018.12.011_bib0009","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1212\/NXI.0000000000000269","article-title":"Early indicators of relapses vs pseudorelapses in neuromyelitis optica spectrum disorder","volume":"3","author":"Kessler","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"Jan(1)","key":"10.1016\/j.msard.2018.12.011_bib0010","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11940-015-0387-9","article-title":"treatment of neuromyelitis optica spectrum disorder: acute, preventive, and symptomatic","volume":"18","author":"Kessler","year":"2016","journal-title":"Curr. Treat. Options Neurol."},{"key":"10.1016\/j.msard.2018.12.011_bib0011","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1177\/1352458512439439","article-title":"Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder?","volume":"18","author":"Kim","year":"2012","journal-title":"Mult. Scler."},{"issue":"April(1)","key":"10.1016\/j.msard.2018.12.011_bib0012","article-title":"Predictors of recurrence following an initial episode of transverse myelitis","volume":"1","author":"Kimbrough","year":"2014","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"Pt 6","key":"10.1016\/j.msard.2018.12.011_bib0013","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/brain\/aws109","article-title":"Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan","volume":"135","author":"Kitley","year":"2012","journal-title":"Brain"},{"issue":"February(2)","key":"10.1016\/j.msard.2018.12.011_bib0014","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ana.24554","article-title":"Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses","volume":"79","author":"Kleiter","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2018.12.011_bib0015","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archneurol.2011.216","article-title":"Failure of Natalizumab to prevent relapses in neuromyelitis optica","volume":"69","author":"Kleiter","year":"2012","journal-title":"Arch. Neurol."},{"issue":"June(7)","key":"10.1016\/j.msard.2018.12.011_bib0017","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1177\/1352458513507822","article-title":"Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients","volume":"20","author":"Kremer","year":"2014","journal-title":"Mult. Scler."},{"issue":"March(3)","key":"10.1016\/j.msard.2018.12.011_bib0018","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1001\/archneurol.2011.1974","article-title":"Low serum vitamin D levels and recurrent inflammatory spinal cord disease","volume":"69","author":"Mealy","year":"2012","journal-title":"Arch. Neurol."},{"issue":"September(9)","key":"10.1016\/j.msard.2018.12.011_bib0019","first-page":"1176","article-title":"Epidemiology of neuromyelitis optica in the United States: a multicenter analysis","volume":"69","author":"Mealy","year":"2012","journal-title":"Arch. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2018.12.011_bib0020","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1352458511431973","article-title":"Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder","volume":"18","author":"Min","year":"2012","journal-title":"Mult. Scler."},{"issue":"September(9)","key":"10.1016\/j.msard.2018.12.011_bib0021","article-title":"Low levels of vitamin D in neuromyelitis optica spectrum disorder: association with disease disability","volume":"9","author":"Min","year":"2014","journal-title":"PLoS One"},{"issue":"August(1-2)","key":"10.1016\/j.msard.2018.12.011_bib0022","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jns.2015.05.011","article-title":"Predictive value of MRI parameters in severity and recovery of first-episode myelitis in aquaporin-4 antibody disease","volume":"355","author":"Murchison","year":"2015","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2018.12.011_bib0023","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/460825","article-title":"Neuromyelitis optica: an antibody-mediated disorder of the central nervous system","volume":"2012","author":"Oh","year":"2012","journal-title":"Neurol. Res. Int."},{"key":"10.1016\/j.msard.2018.12.011_bib0024","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/B978-0-444-63432-0.00006-2","article-title":"Immunopathology: autoimmune glial diseases and differentiation from multiple sclerosis","volume":"133","author":"Popescu","year":"2016","journal-title":"Handb. Clin. Neurol."},{"issue":"April (15)","key":"10.1016\/j.msard.2018.12.011_bib0025","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jneuroim.2016.02.011","article-title":"Factors that impact health-related quality of life in neuromyelitis optica spectrum disorder: anxiety, disability, fatigue and depression","volume":"293","author":"Shi","year":"2016","journal-title":"J. Neuroimmunol."},{"issue":"9","key":"10.1016\/j.msard.2018.12.011_bib0026","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1177\/1352458508094399","article-title":"Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis","volume":"14","author":"Smolders","year":"2008","journal-title":"Mult. Scler."},{"issue":"May(5)","key":"10.1016\/j.msard.2018.12.011_bib0027","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1007\/s00415-014-7298-7","article-title":"Comparative clinical characteristics of neuromyelitis optica spectrum disorders with and without medulla oblongata lesions","volume":"261","author":"Wang","year":"2014","journal-title":"J. Neurol."},{"issue":"July(2)","key":"10.1016\/j.msard.2018.12.011_bib0028","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"September(5)","key":"10.1016\/j.msard.2018.12.011_bib0029","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic's syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"issue":"June(3)","key":"10.1016\/j.msard.2018.12.011_bib0030","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/WCO.0b013e3280be58d8","article-title":"Comparative immunopathogenesis of acute disseminated encephalomyelitis, neuromyelitis optica, and multiple sclerosis","volume":"20","author":"Wingerchuk","year":"2007","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.msard.2018.12.011_bib0031","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1212\/01.wnl.0000254502.87233.9a","article-title":"A secondary progressive clinical course is uncommon in neuromyelitis optica","volume":"68","author":"Wingerchuk","year":"2007","journal-title":"Neurology"},{"issue":"August(9)","key":"10.1016\/j.msard.2018.12.011_bib0032","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1177\/1352458517694086","article-title":"Catastrophic relapses following initiation of dimethyl fumarate in two patients with neuromyelitis optica spectrum disorder","volume":"23","author":"Yamout","year":"2017","journal-title":"Mult. Scler."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103481830539X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103481830539X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:42:48Z","timestamp":1761900168000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103481830539X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":31,"alternative-id":["S221103481830539X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2018.12.011","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term disability in neuromyelitis optica spectrum disorder with a history of myelitis is associated with age at onset, delay in diagnosis\/preventive treatment, MRI lesion length and presence of symptomatic brain lesions","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2018.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}